业绩总结 - 2025年公司预计全年收入增长5%，调整后的EBITDA利润率为21%[48] - 最近12个月（LTM）净销售额为3.52亿美元，同比增长5%[48] - LTM GAAP毛利率为82%[48] - LTM GAAP净收入为4000万美元[48] - 2025年第一季度GAAP毛利润为7160万美元，较2024年第一季度的7170万美元略有下降[60] - 调整后的毛利润为7420万美元，较2024年第一季度的7170万美元增长了3.5%[60] - 调整后的毛利率为84.1%，相比2024年第一季度的84.6%有所下降[60] - 2025年第一季度的GAAP净收入为700万美元，较2024年第一季度的910万美元下降了23.1%[63] - 调整后的净收入为960万美元，较2024年第一季度的990万美元下降了3.0%[63] - 2025年第一季度的调整后EBITDA为1720万美元，较2024年第一季度的1870万美元下降了8.0%[61] - 调整后EBITDA的利润率为19.5%，相比2024年第一季度的22.1%有所下降[61] - 2025年第一季度的每股调整后收益为0.06美元，较2024年第一季度的0.07美元下降了14.3%[63] 现金流与财务状况 - 截至2025年第一季度，净现金余额为8800万美元，较2024年第一季度增加5900万美元[48] - 自由现金流的定义为经营活动提供的净现金减去资本支出，反映公司融资运营和战略投资的能力[58] - 2025年第一季度的资本支出包括设备采购，影响自由现金流的生成能力[58] 市场与产品展望 - 公司在美国有超过300百万的支付者覆盖[9] - 预计2025年外部市场扩展将推动手术业务增长[4] - 预计未来产品的市场接受度和报销环境将影响销售[4] - 公司在慢性和难愈合伤口管理方面拥有超过十年的经验[7] - 公司拥有200多项专利，提供持续扩展的机会[21]

MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual1:1 sessions: Wednesday, Jun ...

MiMedx Group (MDXG) 2025 Conference May 13, 2025 08:15 PM ET Speaker0 On the wound care front, our products are found in virtually every care setting where a patient presents with a chronic or hard to heal wound, and there are lots of them as you can see from this slide. Our portfolio is comprised of a number of products, but I'd like to focus on a few highlights from our portfolio for a moment. First up, EpiFix is our flagship product for the wound market, and as I mentioned, most widely recognized efficac ...

MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estima ...

MiMedx Group (MDXG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Matt Notarianni - Head of Investor RelationsJoseph Capper - CEODoug Rice - Chief Financial OfficerCarl Byrnes - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRoss Osborn - Analyst Operator Good afternoon and thank you for standing by. Welcome to the MieMedix First Quarter twenty twenty five Operating and ...

MiMedx Group (MDXG) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon and thank you for standing by. Welcome to the MieMedix First Quarter twenty twenty five Operating and Financial Results Conference Call. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notariani, Head of Investor Relations for M ...

Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Florida 26-2792552 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charte ...

MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Com ...

MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. MIMEDX is a pioneer and leader focused on helping humans heal. With more than a dec ...